Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insights+: The US FDA New Drug Approvals in April 2023
Insights+: The US FDA New Drug Approvals in April 2023
Shots: The US FDA approved 6 NDAs and 4 BLA in April 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 36 novel products in 2023 In April 2023, the major highlights drugs were, Trikafta approval for children with cystic fibrosis, Qalsody for the treatment of amyotrophic…
May 17, 2023
Disease of the Month - Amyotrophic Lateral Sclerosis (ALS)
Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)
Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research  To continue the series for the disease of the month, PharmaShots brings this month a summary of the disease Amyotrophic Lateral Sclerosis (ALS), a rare…
May 11, 2023
Insights+ Key Biosimilars Events of April 2023
Insights+ Key Biosimilars Events of April 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Sandoz’s Hyrimoz (biosimilar, adalimumab) received EC’s…
May 3, 2023
Insights+: EMA Marketing Authorization of New Drugs in March 2023
Insights+: EMA Marketing Authorization of New Drugs in March 2023
Shots: The EMA approved 4 New Chemical Entity (NCE) and 5 Biologic Drugs in March 2023, leading to treatments for patients and advances in the healthcare industry In March 2023, the major highlights drugs were Reblozyl’s Approval for anemia in adult patients with non-transfusion-dependent beta thalassemia, Pombiliti for late-onset pompe disease PharmaShots has compiled a…
April 27, 2023
Top Performing Drug – Dupixent (April Edition)
Top Performing Drug – Dupixent (April Edition)
Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Dupixent and prepared a curated analysis report for our readers Dupixent is an interleukin-4 receptor alpha antagonist used for the treatment of multiple indications including atopic dermatitis, asthma, eosinophilic esophagitis, etc. PharmaShots…
April 26, 2023
Top Performing Drugs: Proceeding the Series
Top Performing Drugs: Proceeding the Series
Shots: Subsequent to our last year’s series titled “Top Performing Drugs of 2021”, PharmaShots presents a list of 12 high revenue-generating drugs With the ongoing pandemic playing an instrumental role in reshaping the life science industry now and then, it becomes increasingly onerous for the pharmaceutical industry to keep up with the growing global demands…
April 25, 2023
Insights+: The US FDA New Drug Approvals in March 2023
Insights+: The US FDA New Drug Approvals in March 2023
Shots: The US FDA approved 6 NDAs and 1 BLA in March 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 26 novel products in 2023 In March 2023, the major highlights drugs were, Tafinlar + Mekinist approval for BRAF V600E low-grade glioma, Zynyz for metastatic or…
April 19, 2023
Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)
Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)
Shots: With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturing While major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…
April 13, 2023
Disease of the Month: Hemophilia
Disease of the Month: Hemophilia
Shots: To create a wholesome environment for the current and the future generation, it’s totally up to life science companies and decision-makers to embrace and integrate every prospect of the underlying disease conditions and address those issues to find cures To continue the series for disease of the month, PharmaShots brings this month a summary…
April 11, 2023
Insights+ Key Biosimilars Events of March 2023
Insights+ Key Biosimilars Events of March 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of March, Biogen launched Byooviz (biosimilar, ranibizumab) for…
April 5, 2023
Load more